Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study

NCT00620516 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00620516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00620516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regulatory Requisite Post Marketing Surveillance to Assess the Safety and Efficacy of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder 18mcg, q.d.) in Korean COPD Patients: A 30-Day, Open Label, Non-interventional Study
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
March 31, 2004
Completion date
Not reported
Enrollment
3,008 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive